Evelyn Hogg

2.8k total citations
33 papers, 1.2k citations indexed

About

Evelyn Hogg is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Evelyn Hogg has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 17 papers in Virology and 9 papers in Epidemiology. Recurrent topics in Evelyn Hogg's work include HIV Research and Treatment (17 papers), HIV/AIDS drug development and treatment (16 papers) and HIV/AIDS Research and Interventions (15 papers). Evelyn Hogg is often cited by papers focused on HIV Research and Treatment (17 papers), HIV/AIDS drug development and treatment (16 papers) and HIV/AIDS Research and Interventions (15 papers). Evelyn Hogg collaborates with scholars based in United States, South Africa and Kenya. Evelyn Hogg's co-authors include Ian Sanne, Lauren Komarow, Andrew Zolopa, Janet Andersen, William G. Powderly, Alejandro Sanchez, Joseph J. Eron, John W. Mellors, Constance A. Benson and Rajesh T. Gandhi and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Evelyn Hogg

30 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evelyn Hogg United States	16	794	497	488	364	142	33	1.2k
José Ignacio Bernardino Spain	18	501 0.6×	357 0.7×	408 0.8×	403 1.1×	111 0.8×	95	992
Pierre de Truchis France	19	653 0.8×	582 1.2×	276 0.6×	463 1.3×	38 0.3×	42	1.1k
Ellen S. Chan United States	19	952 1.2×	1.2k 2.4×	400 0.8×	464 1.3×	42 0.3×	32	1.9k
José Antonio López Mira Spain	22	486 0.6×	236 0.5×	962 2.0×	130 0.4×	27 0.2×	64	1.6k
Daniel Podzamczer Spain	17	500 0.6×	258 0.5×	343 0.7×	175 0.5×	36 0.3×	35	821
Marco Bongiovanni Italy	15	368 0.5×	240 0.5×	147 0.3×	227 0.6×	30 0.2×	54	696
Hannah Green United Kingdom	14	618 0.8×	542 1.1×	120 0.2×	186 0.5×	28 0.2×	28	962
M. A. Sambeat Spain	17	496 0.6×	422 0.8×	295 0.6×	354 1.0×	41 0.3×	24	879
John P. Phair United States	13	959 1.2×	1.1k 2.3×	552 1.1×	562 1.5×	28 0.2×	22	1.8k
Netanya S. Utay United States	17	418 0.5×	446 0.9×	329 0.7×	293 0.8×	95 0.7×	46	1.1k

Countries citing papers authored by Evelyn Hogg

Since Specialization

Citations

This map shows the geographic impact of Evelyn Hogg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evelyn Hogg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evelyn Hogg more than expected).

Fields of papers citing papers by Evelyn Hogg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evelyn Hogg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evelyn Hogg. The network helps show where Evelyn Hogg may publish in the future.

Co-authorship network of co-authors of Evelyn Hogg

This figure shows the co-authorship network connecting the top 25 collaborators of Evelyn Hogg. A scholar is included among the top collaborators of Evelyn Hogg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evelyn Hogg. Evelyn Hogg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lalloo, Umesh, Lauren Komarow, Judith A. Aberg, et al.. (2023). Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. PLoS ONE. 18(2). e0281580–e0281580. 4 indexed citations

Diepstra, Karen, Elizabeth Barr, David Palm, et al.. (2021). Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Research and Human Retroviruses. 37(6). 489–501. 8 indexed citations

Kitch, Douglas, Elizabeth Connick, Judith A. Aberg, et al.. (2020). Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186. UNC Libraries.

Boltz, Valerie F., Wei Shao, Michael J. Bale, et al.. (2019). Linked dual-class HIV resistance mutations are associated with treatment failure. JCI Insight. 4(19). 13 indexed citations

Gandhi, Rajesh T., Karen T. Tashima, Laura Smeaton, et al.. (2019). Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS). The Journal of Infectious Diseases. 221(9). 1407–1415. 11 indexed citations

Bedimo, Roger, Hanna Mar, Ronald J. Bosch, et al.. (2019). Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. JAIDS Journal of Acquired Immune Deficiency Syndromes. 82(2). e27–e31. 16 indexed citations

Macatangay, Bernard, Rajesh T. Gandhi, R. Brad Jones, et al.. (2019). T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS. 34(1). 15–24. 22 indexed citations

Gross, Robert, Justin Ritz, Michael D. Hughes, et al.. (2019). Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. The Lancet Digital Health. 1(1). e26–e34. 23 indexed citations

Wallis, Carole L., Michael D. Hughes, Justin Ritz, et al.. (2019). Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. Clinical Infectious Diseases. 71(7). e170–e177. 2 indexed citations

10.

Gandhi, Rajesh T., Deborah K. McMahon, Ronald J. Bosch, et al.. (2017). Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathogens. 13(4). e1006285–e1006285. 130 indexed citations

11.

Badal‐Faesen, Sharlaa, Cynthia Firnhaber, Michelle A. Kendall, et al.. (2017). Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. Journal of Clinical Medicine. 6(8). 78–78. 8 indexed citations

12.

Shaffer, Douglas, Michael D. Hughes, Fredrick Sawe, et al.. (2014). Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 66(2). 155–163. 17 indexed citations

13.

Nkanaunena, Kondwani, Yu Zheng, Evelyn Hogg, et al.. (2014). Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS. 28(8). 1135–1142. 15 indexed citations

14.

Luetkemeyer, Anne F., Susan L. Rosenkranz, Darlene Lu, et al.. (2013). Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clinical Infectious Diseases. 57(4). 586–593. 51 indexed citations

15.

Grant, Philip, Lauren Komarow, Janet Andersen, et al.. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLoS ONE. 5(7). e11416–e11416. 119 indexed citations

16.

Zolopa, Andrew, Janet Andersen, Lauren Komarow, et al.. (2009). Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLoS ONE. 4(5). e5575–e5575. 382 indexed citations

17.

Gerber, John G., Douglas Kitch, Carl J. Fichtenbaum, et al.. (2008). Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(4). 459–466. 71 indexed citations

18.

McComsey, Grace A., Michelle A. Kendall, Pablo Tebas, et al.. (2007). Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 21(18). 2473–2482. 119 indexed citations

19.

Margolis, David M., Aprateem Mukherjee, Courtney V. Fletcher, et al.. (2007). The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS. 21(15). 2025–2032. 18 indexed citations

20.

Gallahan, Daniel, Chantal Escot, Evelyn Hogg, & Robert Callahan. (1986). Mammary Tumorigenesis in Feral Species of the Genus Mus. Current topics in microbiology and immunology. 354–361. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact